Dan Ehninger

Dan Ehninger

Auto-generated profile, based on publicly available information

Dan Ehninger

Translational Biogerontology Lab, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2013 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FNFrauke Neff
Frauke Neff
DFDiana Flores-Dominguez
Diana Flores-Dominguez
DRDevon P. Ryan
Devon P. Ryan
MHMarion Horsch
Marion Horsch
SSSusanne Schröder
Susanne Schröder
DEDan Ehninger
Dan Ehninger
Aging is a major risk factor for a large number of disorders and functional impairments. Therapeutic targeting of the aging process may therefore represent an innovative strategy in the quest for novel and broadly effective treatments against age-related diseases. The recent report of lifespan extension in mice treated with the FDA-approved mTOR inhibitor rapamycin represented the first demonstration of pharmacological extension of maximal lifespan in mammals. Longevity effects of rapamycin may, however, be due to rapamycin’s effects on specific life-limiting pathologies, such as cancers, and it remains unclear if this compound actually slows the rate of aging in mammals. Here, we present results from a comprehensive, large-scale assessment of a wide range of structural and functional aging phenotypes, which we performed to determine whether rapamycin slows the rate of aging in male C57BL/6J mice. While rapamycin did extend lifespan, it ameliorated few studied aging phenotypes. A subset of aging traits appeared to be rescued by rapamycin. Rapamycin, however, had similar effects on many of these traits in young animals, indicating that these effects were not due to a modulation of aging, but rather related to aging-independent drug effects. Therefore, our data largely dissociate rapamycin’s longevity effects from effects on aging itself.

1 January 2010 in Frontiers in Neuroscience
Verified
Journal Article
Open access
GKGerd Kempermann
Gerd Kempermann
KFKlaus Fabel
Klaus Fabel
DEDan Ehninger
Dan Ehninger
HBHarish Babu
Harish Babu
PLPerla Leal-Galicia
Perla Leal-Galicia
SWSusanne Wolf
Susanne Wolf
Adult hippocampal neurogenesis is an unusual case of brain plasticity, since new neurons (and not just neurites and synapses) are added to the network in an activity-dependent way. At the behavioral level the plasticity-inducing stimuli include both physical and cognitive activity. In reductionistic animal studies these types of activity can be studied separately in paradigms like voluntary wheel running and environmental enrichment. In both of these, adult neurogenesis is increased but the net effect is primarily due to different mechanisms at the cellular level. Locomotion appears to stimulate the precursor cells, from which adult neurogenesis originates, to increased proliferation and maintenance over time, whereas environmental enrichment, as well as learning, predominantly promotes survival of immature neurons, that is the progeny of the proliferating precursor cells. Surprisingly, these effects are additive: boosting the potential for adult neurogenesis by physical activity increases the recruitment of cells following cognitive stimulation in an enriched environment. Why is that? We argue that locomotion actually serves as an intrinsic feedback mechanism, signaling to the brain, including its neural precursor cells, increasing the likelihood of cognitive challenges. In the wild (other than in front of a TV), no separation of physical and cognitive activity occurs. Physical activity might thus be much more than a generally healthy garnish to leading “an active life” but an evolutionarily fundamental aspect of “activity,” which is needed to provide the brain and its systems of plastic adaptation with the appropriate regulatory input and feedback.

1 February 2011 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
DEDan Ehninger
Dan Ehninger
ASAlcino J. Silva
Alcino J. Silva

12 July 2014 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
DEDan Ehninger
Dan Ehninger
FNFrauke Neff
Frauke Neff
KXKan Xie
Kan Xie
The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains. Here, we review what is currently known about the effects that pharmacological or genetic mammalian target of rapamycin (mTOR) inhibition have on mammalian aging and longevity. Currently available evidence seems to best fit a model, wherein rapamycin extends lifespan by suppressing cancers. In addition the drug has symptomatic effects on some aging traits, such as age-related cognitive impairments.

21 February 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KXKan Xie
Kan Xie
DRDevon P. Ryan
Devon P. Ryan
Brandon PearsonBrandon Pearson
Brandon Pearson
KHKristin S. Henzel
Kristin S. Henzel
FNFrauke Neff
Frauke Neff
DEDan Ehninger
Dan Ehninger
Significance: Aging-associated diseases are increasingly common in an aging global population. However, the contributors and origins of differential risk for unhealthy aging remain poorly understood. Using a mouse model, we found that offspring of aged fathers exhibited a reduced life span and more pronounced aging-associated pathologies than animals sired by young fathers. Tissue of offspring and aged fathers revealed shared epigenetic signatures and showed altered activation states of longevity-related cell signaling. Our results suggest that variability in aging trajectories could derive, in part, from the age at conception of the father, a possibility that warrants human epidemiological investigation.

24 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
KXKan Xie
Kan Xie
FNFrauke Neff
Frauke Neff
AMAstrid Markert
Astrid Markert
JRJan Rozman
Jan Rozman
JAJuan Antonio Aguilar-Pimentel
Juan Antonio Aguilar-Pimentel
DEDan Ehninger
Dan Ehninger
Dietary restriction regimes extend lifespan in various animal models. Here we show that longevity in male C57BL/6J mice subjected to every-other-day feeding is associated with a delayed onset of neoplastic disease that naturally limits lifespan in these animals. We compare more than 200 phenotypes in over 20 tissues in aged animals fed with a lifelong every-other-day feeding or ad libitum access to food diet to determine whether molecular, cellular, physiological and histopathological aging features develop more slowly in every-other-day feeding mice than in controls. We also analyze the effects of every-other-day feeding on young mice on shorter-term every-other-day feeding or ad libitum to account for possible aging-independent restriction effects. Our large-scale analysis reveals overall only limited evidence for a retardation of the aging rate in every-other-day feeding mice. The data indicate that every-other-day feeding-induced longevity is sufficiently explained by delays in life-limiting neoplastic disorders and is not associated with a more general slowing of the aging process in mice.